DELAWARE | 71-0869350 | |
(State or Other Jurisdiction of | (I.R.S. Employer | |
Incorporation or Organization) | Identification No.) |
Large accelerated filer o | Accelerated filer o | Non-accelerated filer o | Smaller reporting company þ | |||
(Do not check if a smaller reporting company) |
Proposed | Proposed | |||||||||||||||||||||
Amount | Maximum | Maximum | Amount Of | |||||||||||||||||||
Title Of | To Be | Offering Price | Aggregate | Registration | ||||||||||||||||||
Securities To Be Registered | Registered (1) | Per Share (2) | Offering Price (2) | Fee | ||||||||||||||||||
Amended and Restated 2007 Equity Incentive Plan
|
7,000,000 | $ | 7.44 | $ | 52,080,000 | $ | 6,047 | |||||||||||||||
Common Stock (par value $0.01 per share)
|
||||||||||||||||||||||
Amended and Restated 2007 Director Option Plan
|
360,798 | $ | 7.44 | $ | 2,684,338 | $ | 312 | |||||||||||||||
Common Stock (par value $0.01 per share)
|
||||||||||||||||||||||
(1) | In addition, pursuant to Rule 416(c) under the Securities Act of 1933, as amended, this Registration Statement also covers an indeterminate number of additional shares of common stock that may be offered or issued in the event of a stock dividend, reverse stock split, split-up, recapitalization, forfeiture of stock under those plans, or other similar event. | |
(2) | Estimated pursuant to Rule 457(c) solely for purposes of calculating the amount of the registration fee, based on the average of the high and low prices of the Registrants common stock reported on June 13, 2011 as reported on The NASDAQ Stock Market, LLC. |
Exhibit | ||||
Number | Exhibit Description | |||
|
||||
4.1 | (1) |
Amicus Therapeutics, Inc Amended and Restated 2007 Equity Incentive Plan
|
||
|
||||
4.2 | (2) |
Amicus Therapeutics, Inc Amended and Restated 2007 Director Option Plan
|
||
|
||||
5.1 |
Opinion of Pepper Hamilton LLP*
|
|||
|
||||
23.1 |
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm*
|
|||
|
||||
23.2 |
Consent of Pepper Hamilton LLP (included in Exhibit 5.1)*
|
|||
|
||||
24 |
Power of Attorney (included in signature page hereto)*
|
(1) | Incorporated by reference to Exhibit 10.1 to the Registrants Form 8-K filed on May 24, 2011. | |
(2) | Incorporated by reference to Exhibit 10.2 to the Registrants Form 8-K filed on June 15, 2010. | |
* | Filed herewith |
AMICUS THERAPEUTICS, INC.
|
||||
By: | /s/ Matthew R. Patterson | |||
Name: | Matthew R. Patterson | |||
Title: | President and Acting Chief Executive Officer |
Signature | Title | |
|
||
/s/ Matthew R. Patterson |
President and Acting Chief Executive Officer
(Principal Executive Officer) |
|
|
||
/s/ Daphne Quimi |
Corporate Controller
(Principal Financial and Accounting Officer) |
|
|
||
/s/ John F. Crowley
|
Director | |
|
||
/s/ Sol J. Barer, Ph.D.
|
Director | |
|
||
/s/ Alexander E. Barkas, Ph.D.
|
Director |
Signature | Title | |
|
||
/s/ James Barrett, Ph.D.
|
Director | |
|
||
/s/ Donald J. Hayden, Jr.
|
Director | |
|
||
/s/ Margaret G. McGlynn, R.Ph.
|
Director | |
|
||
/s/ Michael G. Raab
|
Director | |
|
||
/s/ Glenn P. Sblendorio
|
Director | |
|
||
/s/ James N. Topper, M.D., Ph.D.
|
Director |
Amicus Therapeutics, Inc.
6 Cedar Brook Drive Cranbury, NJ 08512 |
Re: | Registration Statement on Form S-8 |